- On July 1, 2023,
Sunovion Pharmaceuticals Inc.
became part of
Sumitomo Pharma America, Inc., a
biopharmaceutical company focused on
delivering therapeutic...
-
Sepracor for $2.6B in 2010,
renaming its new stand-alone
subsidiary Sunovion.
Under Sunovion management,
Sumitomo Dainippon Pharma was able to successfully...
-
medication was
discovered in
collaboration between PsychoGenics Inc. and
Sunovion Pharmaceuticals (which was
subsequently merged into
Sumitomo Pharma) using...
-
reuptake inhibitor (SNDRI) that was
under development by
Sunovion for the
treatment of attention-deficit
hyperactivity disorder (ADHD) and...
- its U.S.
commercial rights for
Seebri Neohaler and
Utibron Neohaler to
Sunovion Pharmaceuticals. "Product
monograph brand safety updates".
Health Canada...
-
Novartis licensed its U.S.
commercial rights for
Arcapta Neohaler to
Sunovion Pharmaceuticals. "Arcapta
Neohaler (indacaterol)
inhalation powder Initial...
- 1847– )
Strides (1990– )
Stryker (1941– )
Sumitomo (2005– ) Sun (1983– )
Sunovion (formerly Sepracor) (1984– )
Sutro (2003– )
Swedish Orphan Biovitrum (2001–...
-
Wyeth Lurasidone Benzisothiazole Atypical Latuda 2010
Sumitomo Dainippon/
Sunovion Melperone Butyrophenone Disputed Buronil 1967
Lundbeck Mesoridazine...
-
Liming Shao, et al. WO2007081542 (
Sunovion Pharmaceuticals Inc).
Liming Shao &
Jianguo Ma, WO2010091268 (
Sunovion Pharmaceuticals Inc).
Heike Radeke...
- than $27,000 from PACs of
pharmaceutical companies,
including Astellas,
Sunovion, Takeda, Horizon, Eli Lilly, Abbvie,
Alexion and Lundbeck ... According...
